Allergy Therapeutics plc (LON:AGY - Get Free Report) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 4.96 ($0.06) and traded as high as GBX 6.40 ($0.08). Allergy Therapeutics shares last traded at GBX 6.40 ($0.08), with a volume of 928,845 shares.
Allergy Therapeutics Price Performance
The stock has a market capitalization of £305.28 million, a P/E ratio of -106.67, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The business's 50 day simple moving average is GBX 5.23 and its two-hundred day simple moving average is GBX 4.96. The company has a quick ratio of 1.48, a current ratio of 1.40 and a debt-to-equity ratio of 37.22.
Allergy Therapeutics Company Profile
(
Get Free Report)
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Featured Articles
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
